NEUSILIN®: Revolutionizing Oral Suspensions as the Ultimate Stabilizer

THE STRATEGIC SHIFT IN ORAL DRUG DELIVERY

Oral administration remains the gold standard for therapeutic delivery due to its non-invasiveness and high patient compliance. However, for specific patient demographics including pediatrics, geriatrics, and the roughly 16% of the general population suffering from dysphagia, liquid dosage forms are not just a preference but a clinical necessity.

As drug developers increasingly face poorly watersoluble drug entities (comprising nearly 90% of the current pipeline), creating stable, palatable, and effective oral suspensions has become a critical priority. This technical newsletter from Fuji Chemical Industries Co., Ltd. explores how the strategic use of Magnesium Aluminometasilicate (MAS) i.e Neusilin®, a novel synthetic functional excipient, provides a robust pathway for overcoming complex formulation challenges.

WHY NEUSILIN®?

Neusilin® possesses a unique combination of physical and chemical properties that address the common hurdles of drug development:

A CASE STUDY: PERFECTING NSAID SUSPENSIONS

Select NSAIDs are notorious for two major formulation obstacles: poor solubility and a bitter taste. Our recent research highlights how Neusilin® transforms these “limited” formulations into high-performing, patientfriendly products.

1. Superior Particle Dispersion

Microscopic analysis demonstrates that Neusilin®, when used at optimized ratios, results in evenly dispersed, smaller particles with minimal aggregation. This is a stark contrast to traditional compositions, which often exhibit large, aggregated particles and non-uniform distribution.

2. Indirect Taste Masking

Neusilin® contributes to patient acceptability by effectively encapsulating drug particles. This barrier
formation:

• Shields direct contact with taste receptors
• Prevents localized high concentrations of bitter drugs in the suspension
• Reduces the need for excessive flavoring agents or sweeteners, which is vital for pediatric adherence

3. Controlled Dissolution Rates

Data compares Formulation 1 (with Neusilin®) against Formulation 2 (without Neusilin®). The presence of Neusilin® leads to a significantly more controlled and consistent dissolution rate, whereas formulations without it may fail to achieve reproducible release.

THE SYNERGY: BUILDING A COMPLETE EXCIPIENT SYSTEM

While Neusilin® is a powerful excipient, its full potential is unlocked when integrated into a synergistic system.

The Role of Rheology: Xanthan Gum provides pseudoplastic behavior, ensuring high viscosity at rest to prevent settling, but low viscosity under shear (shaking or pouring) for easy administration. This “shear-thinning” is critical for patients using enteral feeding tubes.

Continue reading and see the full Pharmaceutical Technical Newsletter on NEUSILIN®: Revolutionizing Oral Suspensions as the Ultimate Stabilizer here:

(click the picture to download the technical newsletter)

MORE ON FUJI

Source: Fuji Chemical Industries technical newsletter NEUSILIN®: Revolutionizing Oral Suspensions as the Ultimate Stabilizer

Read also the other Technical Newsletter of Fuji Chemical Industries here:

• Issue 06 – The Cost-Effective Solution For Producing High-Quality Orally Disintegrating Tablets (ODTs) 
• Issue 07 – Unveiling Neusilin US2´s Prowness
• Special Issue – The Potential for a Ban on TiO2 (E171) use in Pharmaceuticals
• Special Issue – pH Independent Bi-layer Self-microemulsifying Tablets (SMETs) of Candesartan Cilexetil with Fujicalin® and Neusilin®
• Newsletter March 2026: Elevating The Innovators Standard: Optimizing Steglujan® – Type Formulations With Fujicalin®

Do you need more information or a sample of Fuji Chemical Industries excipients?